Skip to main content
Clinical Trials/NCT04978636
NCT04978636
Active, not recruiting
Not Applicable

The eFfect of cOntinuous Low Tidal Volume Ventilation With Hyperoxia Avoidance During CardiopUlmonary Bypass "FOCUS" Trial Blood Samples

The Cleveland Clinic1 site in 1 country5,502 target enrollmentSeptember 20, 2021
ConditionsCardiac Surgery

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Surgery
Sponsor
The Cleveland Clinic
Enrollment
5502
Locations
1
Primary Endpoint
Occurrence of Composite including STS 30 day Mortality and postoperative pulmonary complications
Status
Active, not recruiting
Last Updated
4 months ago

Overview

Brief Summary

This is a multi-institutional study (CCF, UPMC, OSU) evaluating different ventilation strategies during cardiopulmonary bypass on mortality and postoperative pulmonary complications, with sub-study investigating 8-iso-prostaglandin F2a and sRAGE levels.

Detailed Description

The investigators will evaluate the effect of low tidal volume with varying FiO2 fractions during cardiopulmonary bypass on postoperative mortality and pulmonary complications. This will be a prospective, pragmatic, cluster randomized trial including all eligible adult cardiac surgical patients requiring cardiopulmonary bypass. Each week, all operating rooms will be randomized to one of three possible ventilation strategies during the period of cardiopulmonary bypass: 1) continuous low tidal volume ventilation with inspired oxygen fraction at 1.0, 2) continuous low tidal volume ventilation with inspired oxygen fraction at 0.21, and 3) no ventilation (apnea). The investigators will anticipate increase in plasma sRAGE and 8-iso-prostaglandin F2a levels in all three groups of patients during CPB with the highest levels immediately after cross-clamp release. The investigators will anticipate significant difference with at least 25% lower sRAGE levels in this group. The sub-study will also provide preliminary data on the behavior of the 8-iso-prostaglandin F2a which will be useful in further investigation of other targeted interventions to reduce ischemia-reperfusion injury to the lung during routine cardiac surgical operations.

Registry
clinicaltrials.gov
Start Date
September 20, 2021
End Date
March 30, 2027
Last Updated
4 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Marta Kelava, MD

PI

The Cleveland Clinic

Eligibility Criteria

Inclusion Criteria

  • \>18 years of age
  • Male and female patients undergoing elective cardiac surgeries requiring cardiopulmonary bypass.

Exclusion Criteria

  • Emergency surgeries, surgeries requiring lung isolation and one-lung ventilation (OLV), heart or lung transplants, and mechanical circulatory support device implantation pulmonary thrombendarterectomies.
  • Surgeries requiring one-lung ventilation will be excluded because of the inability to employ study intervention and the differential treatment of the lungs likely confounding any potential effect from the planned intervention.
  • Lung transplant surgeries will be excluded for similar reasons as well as other confounding effects affecting the primary composite outcome.
  • Heart transplants and mechanical circulatory support device implantation surgeries will be excluded because these patients already receive intervention as part of the institutional protocol at the primary study site.

Outcomes

Primary Outcomes

Occurrence of Composite including STS 30 day Mortality and postoperative pulmonary complications

Time Frame: Within 30 days of surgery

Composite including STS 30-day mortality and postoperative pulmonary complications defined a early respiratory failure defined as PaO2/FiO2 ratio\<200 mmHg at any time within the first 24 hours of ICU admission, postoperative reintubation during the hospital stay, prolonged ventilation, pneumonia, pleural effusion requiring drainage, pneumothorax requiring intervention, and readmission due to: pleural effusion requiring intervention, or pneumonia.

Secondary Outcomes

  • CPB time(During surgery)
  • 30-day mortality(Within 30 days of surgery)
  • Hospital LOS(Within 30 days of surgery)
  • Need for tracheostomy(Within 30 days of surgery)
  • ICU LOS(Within 30 days of surgery)
  • Reintubation(Within 30 days of surgery)
  • Early respiratory failure - PaO2/FiO2 ratio < 200 mmHg at any time within the first 24 hours of ICU admission(24 hours)
  • Pleural effusion requiring drainage(Within 30 days of surgery)
  • Pneumonia(Within 30 days of surgery)
  • Readmission(within 30 days of surgery)

Study Sites (1)

Loading locations...

Similar Trials